Philogen SpAMIL:PHIL +2.37%59 PS Ratio is 3.06 as of Jul. 02, 2026, which is 90% below its 10-year median of 31.30. GuruFocus rates MIL:PHIL with a GF Score™ of 59/100 and a GF Value™ of €227.90 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Philogen SpA ranks better than 76.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Philogen SpA's share price is €23.75.
Philogen SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €7.77. Hence, Philogen SpA's PS Ratio for today is 3.06.
The historical rank and industry rank for Philogen SpA's PS Ratio or its related term are showing as below:
MIL:PHIL'
s PS Ratio Range Over the Past 10 Years
Min: 2.56 Med: 31.3 Max: 237.46
Current: 3.06
During the past 6 years, Philogen SpA's highest PS Ratio was 237.46. The lowest was 2.56. And the median was 31.30.
MIL:PHIL's PS Ratio is ranked better than 76.85% of 933
companies
in the Biotechnology industry
Industry Median: 9.46
vs MIL:PHIL: 3.06
During the past 12 months, the average Revenue per Share Growth Rate of Philogen SpA was 325.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 137.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 139.30% per year.
During the past 6 years, Philogen SpA's highest 3-Year average Revenue per Share Growth Rate was 207.70% per year. The lowest was 63.70% per year. And the median was 137.30% per year.
Back to Basics: PS Ratio
Philogen SpA (MIL:PHIL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Philogen SpA PS Ratio Related Terms
Philogen SpA PS Ratio Historical Data
* Premium members only.
The historical data trend for Philogen SpA's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Philogen SpA's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's PS Ratio distribution charts can be found below:
* The bar in red indicates where Philogen SpA's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Philogen SpA's PS Ratio for today is calculated as
Philogen SpA's Share Price of today is €23.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Philogen SpA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €7.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Philogen SpA (MIL:PHIL) has a PS Ratio of 3.06 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Philogen SpA and its competitors. This is 90% below median its historical median of 31.30. Over the past decade, Philogen SpA's PS Ratio has ranged from 2.56 to 237.46. According to the industry distribution chart, Philogen SpA ranks #216 out of 933 companies in the Biotechnology industry, placing it in the top 23.2%.
Is Philogen SpA's PS Ratio too high?
Philogen SpA's current PS Ratio of 3.06 is 90% below median its 10-year median of 31.30. Over the past 10 years, this metric has ranged from a low of 2.56 to a high of 237.46. The Biotechnology industry median PS Ratio is 9.46. Philogen SpA's value of 3.06 is 67.7% below this industry median. Based on the distribution chart, Philogen SpA ranks #216 out of 933 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #216 out of 933 companies for PS Ratio. This places Philogen SpA in the top 23% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.46. Philogen SpA's value of 3.06 is 67.7% below this benchmark. Historically, Philogen SpA's own PS Ratio has ranged from 2.56 to 237.46 over the past decade. While the company's 10-year median is 31.30 vs. the industry median of 9.46, Philogen SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current PS Ratio of 3.06 is 67.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Philogen SpA and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current PS Ratio is 3.06, which is 90% below median its own 10-year median of 31.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.90, compared to a current price of €23.75 — trading 89.6% below its estimated fair value. The current PS Ratio is 3.06, which is 90% below median its 10-year median of 31.30 and 67.7% below the Biotechnology industry median of 9.46. Philogen SpA's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current PS Ratio is 3.06 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.75 is trading 89.6% below its estimated GF Value™ of €227.90.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
PS Ratio: 3.06 (90% below median its 10-year median of 31.30)
GF Value™: €227.90 vs. price of €23.75 (89.6% below fair value)
Industry Position: 67.7% below the Biotechnology median (#216 of 933)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
59GF Score
Get the complete analysis for MIL:PHIL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
